Sanofi India growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Dec 2025FY25Dec 2024FY24Dec 2023FY22 and earlierAlpha Plus
−8.7%−29.4%+2.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+0.1%−39.0%+14.1%
−0.0%−40.6%+15.4%
−21.0%−31.4%−2.8%
−20.8%−31.7%−2.8%
−22.1%−6.0%−17.2%
−12.9%−15.3%−20.4%
−5.1%+100.0%−42.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFI₹3,189.50

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,336 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
FY26
31/12/2025
Last 12M
30/09/2026
Revenue Growth—+2.9-29.4-8.7—
EBITDA Growth—+14.1-39.0+0.1—
EBIT Growth—+15.4-40.6-0.0—
Net Income Growth—-2.8-31.4-21.0—
EPS Growth—-2.8-31.7-20.8—
Total Assets Growth—-17.2-6.0-22.1—
Total Equity Growth—-20.4-15.3-12.9—
Cash from Operations Growth—-42.1+100.0-5.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.